New CDC population data from 2023 show that in 23 states more than one in three adults (35%) has obesity. Before 2013, no state had an adult obesity prevalence at or above 35%. Currently, at least one ...

Demand forweight-loss drugs has grown at an astonishing rate in recent years, driving share prices of healthcare giants such ...

Discover the revival of the biotech sector, with IPOs resurging and promising weight loss drug potential, despite facing ...

We recently published a list of 10 Best Major Stocks to Invest In According to Analysts. In this article, we are going to ...

Roche told investors on Monday that it plans to make significant cuts to both the cost and time it takes for it to develop ...

Rivus already announced in August that the trial hit its key endpoint, but today fleshed out that win with some figures.

Some oncologists are turning to GLP-1 agents to help patients shed excess pounds, with the goal of improving cancer outcomes.

When people think of epidemics, they might think they’re caused only by viruses or other germs. But as public health experts, we know that’s just part of the story. Commerce can cause epidemics, too.

Roche said on Monday that three early-stage obesity and diabetes drug candidates from its acquisition of Carmot Therapeutics ...

Roche said it plans to focus on five key therapeutic areas as part of its new pharma strategy through 2030. The company will prioritize work in the areas of neurology, oncology and hematology, ...

Amgen's strong dividend growth, with a 2.8% yield and consistent hikes since 2011. Read what makes AMGN stock is a worthy ...